Cellectar Biosciences Inc. is a clinical biopharmaceutical company based in Florham Park, New Jersey, focused on developing innovative cancer therapies through its proprietary phospholipid drug conjugate (PDC) platform. This technology facilitates the precise targeting of tumor cells, enhancing therapeutic efficacy while reducing adverse effects. With a promising pipeline aimed at addressing significant unmet oncology needs, Cellectar is strategically positioned to make a substantial impact in cancer treatment, representing a compelling investment opportunity for institutional investors interested in pioneering advancements in the biopharmaceutical sector. Show more

Location: 100 CAMPUS DRIVE, FLORHAM PARK, NJ, UNITED STATES, 07932, Florham Park, NJ, 07932, USA | Website: https://www.cellectar.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

13.65M

52 Wk Range

$2.45 - $20.59

Previous Close

$3.24

Open

$3.24

Volume

39,176

Day Range

$3.16 - $3.36

Enterprise Value

3.434M

Cash

12.55M

Avg Qtr Burn

-4.275M

Insider Ownership

4.50%

Institutional Own.

7.69%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Iopofosine (CLR 131) Details Multiple myeloma, Cancer, High Refractory Multiple Myeloma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Iopofosine (CLR 131) Details Waldenstrom macroglobulinemia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CLR 125 Details Triple-negative breast cancer	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CLR 121125 Details Triple-negative breast cancer	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Iopofosine (CLR 131) Details Children, Adolescents and Young Adults With Inoperable Relapsed or Refractory High-Grade Glioma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Iopofosine (CLR 131) + EBRT Details Head and neck cancer, Head and neck squamous cell carcinoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.